Screener
Immunome IMNM Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Immunome’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344636
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $217,706 | $653,482 |
| Marketable securities | 302,290 | — |
| Prepaid expenses and other current assets | 18,453 | 7,295 |
| Total current assets | 538,449 | 660,777 |
| Property and equipment, net | 17,359 | 14,636 |
| Operating right-of-use assets | 3,942 | 2,978 |
Item 1. Financial Statements.
FAQ
- What is Immunome's short-term investments?
- Immunome (IMNM) reported short-term investments of $302.29M in Q2 2026.
- How has Immunome's short-term investments changed year-over-year?
- Immunome's short-term investments increased by 143.5% year-over-year, from $124.16M to $302.29M.
- What is the long-term trend for Immunome's short-term investments?
- Over 2 years (2023 to 2025), Immunome's short-term investments has grown at a -100.0% compound annual growth rate (CAGR), from $39.46M to $0.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Immunome's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude